Go directly to:

• ESCMID publications
• Medical Guidelines
• EITaF
• EUCAST
• Position papers
• Publications from Study Groups
• Study group contributions to publications
• Publications from recipients of research grants

• ESCMID-an international Europe-based society committed to fostering cross-border
  collaboration and education to improve patient care.
  Poljak M, Akova M, Friedrich AW, et al. Clin Microbiol Infect 2018;24:1-2. doi: 10.1016/j.cmi.2017.05.024.

• Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an
  international cross-sectional survey.
  Alves J, Alp E, Koulenti D, et al. Eur J Clin Microbiol Infect Dis 2018. doi: 10.1007/s10096-017-3175-5.

• How are trainees in clinical microbiology and infectious diseases supervised in
  Europe?An international cross-sectional questionnaire survey by the Trainee
  Association of ESCMID.
  Palacios-Baena ZR, Zapf TC, Ong DSY, et al. Eur J Clin Microbiol Infect Dis 2018;37:2381-2387. doi: 10.1007/s10096-018-3386-4.
  
  

• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Ullmann AJ, Aguado JM, et al. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. 
• Guidance document for prevention of Clostridium difficile infection in acute healthcare settings. Tschudin-Sutter S, Kuijper EJ et al. Clin Microbiol Infect. 2018 Oct;24(10):1051-1054. doi: 10.1016/j.cmi.2018.02.020.

• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus
  document on the safety of targeted and biologic therapies: an infectious diseases
  perspective—cell surface receptors and associated signaling pathways.
  Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. Clin Microbiol Infect 2018;24:S41-S52. doi: 10.1016/j.cmi.2017.12.027.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22,
  CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
  Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. Clin Microbiol Infect 2018;24:S83-S94. doi: 10.1016/j.cmi.2018.03.022.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
  Baddley JW, Cantini F, Goletti D, et al. Clin Microbiol Infect 2018;24:S10-S20. doi: 10.1016/j.cmi.2017.12.025
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
  Reinwald M, Silva JT, Mueller NJ, et al. Clin Microbiol Infect 2018;24:S53-S70. doi: 10.1016/j.cmi.2018.02.009
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and
  CD52).
  Mikulska M, Lanini S, Gudiol C, et al. Clin Microbiol Infect 2018;24:S71-S82. doi: 10.1016/j.cmi.2018.02.003.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [II]: agents targeting interleukins,
  immunoglobulins and complement factors).
  Winthrop KL, Mariette X, Silva JT, et al. Clin Microbiol Infect 2018;24:S21-S40. doi: 10.1016/j.cmi.2018.02.002.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-
  phosphate receptor modulators and proteasome inhibitors).
  Redelman-Sidi G, Michielin O, Cervera C, et al. Clin Microbiol Infect 2018;24:S95-S107. doi: 10.1016/j.cmi.2018.01.030.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Introduction).
  Fernández-Ruiz M, Meije Y, Manuel O,et al. Clin Microbiol Infect 2018;24:S2-S9. doi: 10.1016/j.cmi.2018.01.029
• Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH)
  Consensus Document on the safety of targeted and biological therapies:
  an infectious diseases perspective.
  Aguado JM, Manuel O. Clin Microbiol Infect 2018;24 S1. doi: 10.1016/j.cmi.2018.04.02
• To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a
  position paper of ESGBOR, the ESCMID study group for Lyme borreliosis.
  Dessau RB, van Dam AP, Fingerle V, et al. Clin Microbiol Infect 2018;24:118-124. doi: 10.1016/j.cmi.2017.08.025.

• Emerging infections-an increasingly important topic: review by the Emerging Infections
  Task Force.
  Petersen E, Petrosillo N, Koopmans M; ESCMID Emerging Infections Task Force Expert Panel. Clin Microbiol Infect 2018;24:369-375. doi: 10.1016/j.cmi.2017.10.035.

• How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the
  detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-
  containing agar plates.
  Guinea J, Verweij PE, Meletiadis J, Mouton JW, Barchiesi F, Arendrup MC; Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). Clin Microbiol Infect 2018 pii: S1198-743X(18)30630-X. doi: 10.1016/j.cmi.2018.09.008.
• A plea from EUCAST for standardization of disc susceptibility testing antimicrobial codes.
  Turnidge J, Lina G, Giske C; European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. Clin Microbiol Infect 2018;24:1345. doi: 10.1016/j.cmi.2018.08.007.
• Colistin antimicrobial susceptibility testing—can the slow and challenging be replaced
  by the rapid and convenient?
  Giske CG, Kahlmeter G. Clin Microbiol Infect 2018;24:93-94. doi: 10.1016/j.cmi.2017.10.007
• Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC
  products against standard broth microdilution for Escherichia coli, Klebsiella
  pneumoniae , Pseudomonas aeruginosa , and Acinetobacter spp.
  Matuschek E, Åhman J, Webster C, Kahlmeter G. Clin Microbiol Infect 2018;24:865-870. doi: 10.1016/j.cmi.2017.11.020
• Development of EUCAST zone diameter breakpoints and quality control criteria for
  ceftazidime-avibactam 10-4 μg.
  Koeth LM, Matuschek E, Kahlmeter G, Stone G. Eur J Clin Microbiol Infect Dis 2018;3:1047-1053. doi: 10.1007/s10096-018-3215-9
• MIC-based dose adjustment: facts and fables—authors’ response.
  Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. J Antimicrob Chemother 2018;73:2585-2586. doi: 10.1093/jac/dky195
  
  

ESGAI

• Performance of mass spectrometric identification of clinical Prevotella species
  using the VITEK MS system: A prospective multi-center study.
  Ulger Toprak N, Alida CMV, Urban E, et al. Anaerobe 2018 ;54:205-209. doi: 10.1016/j.anaerobe.2018.05.016.
• A multicenter survey of antimicrobial susceptibility of Prevotella species as
  determined by Etest methodology.
  Ulger Toprak N, Veloo ACM, Urban E, et al. Anaerobe 2018;52:9-15. doi: 10.1016/j.anaerobe.2018.05.005. 
• Antimicrobial susceptibility testing of Bacteroides fragilis using the MALDI
  Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA).
  Justesen US, Acar Z, Sydenham TV, Johansson Å; ESGAI (ESCMID Study Group on Anaerobic Infections). Anaerobe 2018;54:236-239. doi: 10.1016/j.anaerobe.2018.02.007.
• How to isolate, identify and determine antimicrobial susceptibility of anaerobic
  bacteria in routine laboratories.
  Nagy E, Boyanova L, Justesen US; ESCMID Study Group of Anaerobic Infections. Clin Microbiol Infect 2018;24:1139-1148. doi: 10.1016/j.cmi.2018.02.008.
• The International Anaerobe Quality Assurance Scheme (IAQAS).
  Morris T, Copsey-Mawer S, Hughes H; ESCMID Study Group for Anaerobic Infections (ESGAI). Anaerobe 2018;49:132. doi: 10.1016/j.anaerobe.2017.10.009.
• Sample preparation method influences direct identification of anaerobic bacteria
  from positive blood culture bottles using MALDI-TOF MS.
  Jeverica S, Nagy E, Mueller-Premru M, Papst L. Anaerobe 2018;54:231-235. doi: 10.1016/j.anaerobe.2018.05.003.
• The first characterized carbapenem-resistant Bacteroides fragilis strain from Croatia
  and the case study for it.
  Bogdan M, Perić L, Ördög K, Vuković D, Urbán E, Sóki J. Acta Microbiol Immunol Hung 2018;65:317-323. doi: 10.1556/030.65.2018.024.
• Bacteroides fragilis: A whole MALDI-based workflow from identification to
  confirmation of carbapenemase production for routine laboratories.
  Cordovana M, Kostrzewa M, Sóki J, Witt E, Ambretti S, Pranada AB. Anaerobe 2018;54:246-253. doi: 10.1016/j.anaerobe.2018.04.004

ESGAP

• Human resources estimates and funding for antibiotic stewardship teams are
  urgently needed: authors' response.
  Pulcini C, Beovic B, Howard P, Mendelson M. Clin Microbiol Infect 2018;24:557. doi: 10.1016/j.cmi.2018.01.009.

• Defensive medicine among antibiotic stewards: the international ESCMID
  AntibioLegalMap survey.
  Tebano G, Dyar OJ, Beovic B, Béraud G, Thilly N, Pulcini C. J Antimicrob Chemother 2018;73:1989-1996. doi: 10.1093/jac/dky098

• Perceptions, attitudes, and practices of French junior physicians regarding
  antibiotic use and resistance.
  Lévin C, Thilly N, Dousak M, et al. Med Mal Infect 2018. In press. doi: 10.1016/j.medmal.2018.09.003.efi

• Legal framework of antimicrobial stewardship in hospitals (LEASH): a European
  Society of Clinical Microbiology and Infectious Diseases (ESCMID) cross-sectional
  international survey.
  Beović B, Pulcini C, Dumartin C, et al. Int J Antimicrob Agents 2018;52:616-621. doi: 10.1016/j.ijantimicag.2018.07.019.

• Do medical students feel prepared to prescribe antibiotics responsibly? Results
  from a cross-sectional survey in 29 European countries.
  Dyar OJ, Nathwani D, Monnet DL, et al. J Antimicrob Chemother 2018;73:2236-2242. doi: 10.1093/jac/dky150.

ESGB

• Cross-disciplinary biofilm research-an introduction to the fourth thematic issue
  on biofilms.
  Coenye T, Kjellerup B. Pathog Dis 2018;76. doi: 10.1093/femspd/fty061.

EFWISG

• Discrimination of non-typhoid Salmonella serogroups and serotypes by Fourier
  Transform Infrared Spectroscopy: A comprehensive analysis.
  Campos J, Sousa C, Mourão J, Lopes J, Antunes P, Peixe L. Int J Food Microbiol 2018;285:34-41. doi: 10.1016/j.ijfoodmicro.2018.07.005

ESGIB

• Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis.
  A systematic review and meta-analysis. 
  Rupprecht TA, Manz KM, Fingerle V, et al. Clin Microbiol Infect 2018;24:1234-1240. doi: 10.1016/j.cmi.2018.04.007
• Novel and preclinical treatment strategies in pneumococcal meningitis.
  Bewersdorf JP, Grandgirard D, Koedel U, Leib SL. Curr Opin Infect Dis 2018;31:85-92. doi: 10.1097/QCO.0000000000000416
• Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis:
  Results of the Ege study.
  Sipahi OR, Mermer S, Demirdal T, et al. Clin Neurol Neurosurg 2018;172:31-38. doi: 10.1016/j.clineuro.2018.06.008.

ESGBOR

• To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a
  position paper of ESGBOR, the ESCMID study group for Lyme borreliosis.
  Dessau RB, van Dam AP, Fingerle V, et al. Clin Microbiol Infect. 2018;24:118-124. doi: 10.1016/j.cmi.2017.08.025.
• Impact of pre-existing treatment with statins on the course and outcome of
  tick-borne encephalitis.
  Bogovič P, Lusa L, Stupica, et al. PLoS One 2018;13. doi: 10.1371/journal.pone.0204773.
• The genus Borrelia reloaded.
  Margos G, Gofton A, Wibberg D, et al. PLoS One 2018;13:e0208432. doi: 10.1371/journal.pone.0208432.

ESGBIES

• Towards an improved diagnosis of bloodstream infection: promises and hurdles.
  Lamy B, Sundqvist M. Clin Microbiol Infect 2018;24:933-934. doi: 10.1016/j.cmi.2018.02.025
• A prospective multicentre study of the epidemiology and outcomes of bloodstream
  infection in cirrhotic patients.
  Bartoletti M, Giannella M, Lewis R, et al. Clin Microbiol Infect 2018;24:546.e1-546.e8. doi: 10.1016/j.cmi.2017.08.001
• Comparison of predictors and mortality between bloodstream infections caused by
  ESBL-producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
  Scheuerman O, Schechner V, Carmeli Y, et al. Infect Control Hosp Epidemiol 2018;39:660-667. doi: 10.1017/ice.2018.63
• Predictors of outcome in patients with severe sepsis or septic shock due to
  extended-spectrum β-lactamase-producing Enterobacteriaceae.
  Russo A, Falcone M, Gutiérrez-Gutiérrez B, et al. Int J Antimicrob Agents 2018;52:577-585. doi: 10.1016/j.ijantimicag.2018.06.018

ESGCD

• The pitfalls of laboratory diagnostics of Clostridium difficile infection.
  Krutova M, Wilcox MH, Kuijper EJ. Clin Microbiol Infect 2018;24:682-683. doi: 10.1016/j.cmi.2018.02.026.
• The ESCMID Study Group for Clostridium difficile: History, Role and Perspectives.
  Coia JE, Kuijper EJ. Adv Exp Med Biol 2018;1050:245-254. doi: 10.1007/978-3-319-72799-8_14.
• New insights into transmission of Clostridium difficile infection—narrative review.
  Durovic A, Widmer AF, Tschudin-Sutter S. Clin Microbiol Infect 2018;24:483-492. doi: 10.1016/j.cmi.2018.01.027
• How to: Surveillance of Clostridium difficile infections.
  Krutova M, Kinross P, Barbut F, et al. Clin Microbiol Infect 2018;24:469-475. doi: 10.1016/j.cmi.2017.12.008
• How to: diagnose infection caused by Clostridium difficile.
  Gateau C, Couturier J, Coia J, Barbut F. Clin Microbiol Infect 2018;24:463-468. doi: 10.1016/j.cmi.2017.12.005
• C. difficile infection - Can we do better?
  Coia J. Clin Microbiol Infect 2018;24:450-451. doi: 10.1016/j.cmi.2017.12.009.
• Microbiologic factors affecting Clostridium difficile recurrence.
  Chilton CH, Pickering DS, Freeman J. Clin Microbiol Infect 2018;24:476-482. doi: 10.1016/j.cmi.2017.11.017.
• Trends in mortality following Clostridium difficile infection in Scotland, 2010-2016:
  a retrospective cohort and case-control study.
  Banks A, Moore EK, Bishop J, et al. J Hosp Infect 2018;100:133-141. doi: 10.1016/j.jhin.2018.07.023.

ESGCP

• Toxoplasmosis in transplant recipients, Europe, 2010–2014.
  Robert-Gangneux F, Meroni V, Dupont D, et al. Emerg Infect Dis 2018;24:1497-1504. doi: 10.3201/eid2408.180045

ESGFOR

• Post-mortem microbiology in sudden death: Sampling protocols proposed in
  different clinical settings.
  Fernández-Rodríguez A, Burton JL, Andreoletti L, et al. Clin Microbiol Infect 2018. doi: 10.1016/j.cmi.2018.08.009

ESGICH

• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus
  document on the safety of targeted and biologic therapies: an infectious diseases
  perspective—cell surface receptors and associated signaling pathways.
  Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I. Clin Microbiol Infect 2018;24:S41-S52. doi: 10.1016/j.cmi.2017.12.027.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22,
  CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
  Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M. Clin Microbiol Infect 2018;24:S83-S94. doi: 10.1016/j.cmi.2018.03.022.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
  Baddley JW, Cantini F, Goletti D, et al. Clin Microbiol Infect 2018;24:S10-S20. doi: 10.1016/j.cmi.2017.12.025
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
  Reinwald M, Silva JT, Mueller NJ, et al. Clin Microbiol Infect 2018;24:S53-S70. doi: 10.1016/j.cmi.2018.02.009
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and
  CD52).
  Mikulska M, Lanini S, Gudiol C, et al. Clin Microbiol Infect 2018;24:S71-S82. doi: 10.1016/j.cmi.2018.02.003.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Soluble immune effector molecules [II]: agents targeting interleukins,
  immunoglobulins and complement factors).
  Winthrop KL, Mariette X, Silva JT, et al. Clin Microbiol Infect 2018;24:S21-S40. doi: 10.1016/j.cmi.2018.02.002.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-
  phosphate receptor modulators and proteasome inhibitors).
  Redelman-Sidi G, Michielin O, Cervera C, et al. Clin Microbiol Infect 2018;24:S95-S107. doi: 10.1016/j.cmi.2018.01.030.
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
  Document on the safety of targeted and biological therapies: an infectious diseases
  perspective (Introduction).
  Fernández-Ruiz M, Meije Y, Manuel O,et al. Clin Microbiol Infect 2018;24:S2-S9. doi: 10.1016/j.cmi.2018.01.029
• Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH)
  Consensus Document on the safety of targeted and biological therapies:
  an infectious diseases perspective.
  Aguado JM, Manuel O. Clin Microbiol Infect 2018;24 S1. doi: 10.1016/j.cmi.2018.04.029.
• Re: "Comparison of antipseudomonal betalactams for febrile neutropenia empiric
  therapy: systematic review and network metaanalysis" by Horita et al.
  Averbuch D, Orasch C, Mikulska M, et al. Clin Microbiol Infect 2018;24:662-663. doi: 10.1016/j.cmi.2018.01.012.
• Recommendations for Management of Endemic Diseases and Travel Medicine in
  Solid-Organ Transplant Recipients and Donors: Latin America.
  Clemente WT, Pierrotti LC, Abdala E, et al. Transplantation 2018;102:193-208. doi: 10.1097/TP.0000000000002027.

ESGIE

• Antimicrobial consumption and impact of antimicrobial stewardship programmes in
  long-term care facilities.
  Falcone M, Paul M, Yahav D, et al. Clin Microbiol Infect 2018 pii: S1198-743X(18)30559-7. doi: 10.1016/j.cmi.2018.07.028.
• ESCMID postgraduate education course: regional capacity building for integration of
  next-generation sequencing in the clinical microlab.
  Motro Y, Carriço JA Friedrich AW, Rossen JWA, Moran-Gilad J. Microbes Infect 2018;20:275-280. doi: 10.1016/j.micinf.2018.02.006.
• Bacterial next generation sequencing (NGS) made easy.
  Tassios PT, Moran-Gilad J. Clin Microbiol Infect. 2018;24:332-334. doi: 10.1016/j.cmi.2018.03.00
• Practical issues in implementing whole-genome-sequencing in routine diagnostic
  microbiology.
  Rossen JWA, Friedrich AW, Moran-Gilad J; ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD). Clin Microbiol Infect 2018;24:355-360. doi: 10.1016/j.cmi.2017.11.001

ESGNI

• Variability in contact precautions to control the nosocomial spread of multi-drug
  resistant organisms in the endemic setting: a multinational cross-sectional survey.
  Gysin DV, Cookson B, Saenz H, Dettenkofer M, Widmer AF; ESCMID Study Group for Nosocomial Infections (ESGNI). Antimicrob Resist Infect Control 2018;7:81. doi: 10.1186/s13756-018-0366-5.

ESGVM

• Optimization of antimicrobial treatment to minimize resistance selection.
  Guardabassi L, Apley M, Elmderdahl Olsen J, Toutain PL, Weese S. Microbiol Spectr 2018 doi: 10.1128/microbiolspec.ARBA-0018-2017.

ESGMD

• How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry.
  Alcaide F, Amlerová J, Bou G, et al. Clin Microbiol Infect 2018;24:599-603. doi: 10.1016/j.cmi.2017.11.012.
• Diagnosis of bloodstream infections from positive blood cultures and directly from blood samples:
  recent developments in molecular approaches.
  Peker N, Couto N, Sinha B, Rossen JW. Clin Microbiol Infect 2018;24:944-955. doi: 10.1016/j.cmi.2018.05.007.
• Contaminants in blood cultures: importance, implications, interpretation and prevention.
  Dargère S, Cormier H, Verdon R. Clin Microbiol Infect 2018;24:964-969. doi: 10.1016/j.cmi.2018.03.030.

ESGHAMI

• Targeting mechanisms of tailed bacteriophages.
  Nobrega FL, Vlot M, de Jonge PA, et al. Nat Rev Microbiol 2018;16:760-773. doi: 10.1038/s41579-018-0070-8
• Formula feeding predisposes neonatal piglets to Clostridium difficile gut infection.
  Grześkowiak Ł, Martínez-Vallespín B, Dadi TH, et al. J Infect Dis 2018;217:1442-1452. doi: 10.1093/infdis/jix567
• Metagenomic characterization of the human intestinal microbiota in fecal samples from
  STEC-infected patients.
  Gigliucci F, von Meijenfeldt FAB, Knijn A, et al. Front Cell Infect Microbiol 2018;8. doi: 10.3389/fcimb.2018.00025
• Towards predicting the environmental metabolome from metagenomics with a mechanistic model.
  Garza DR, van Verk MC, Huynen MA, Dutilh BE. Nat Microbiol 2018;3:456-460. doi: 10.1038/s41564-018-0124-8
• Large-scale genomic analysis shows association between homoplastic genetic variation in
  Mycobacterium tuberculosis genes and meningeal or pulmonary tuberculosis.
  Ruesen C, Chaidir L, van Laarhoven A, et al. BMC Genomics 2018;19:122. doi: 10.1186/s12864-018-4498-z
• Establishing normal metabolism and differentiation in hepatocellular carcinoma cells by
  culturing in adult human serum.
  Steenbergen R, Oti M, Ter Horst R, et al. Sci Rep 2018;8:11685. doi: 10.1038/s41598-018-29763-2
• Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. 
  Biehl LM, Cruz Aguilar R, Farowski F, et al. Infection 2018;46:871-874. doi: 10.1007/s15010-018-1190-9

ESGS

• European external quality assessments for identification, molecular typing and
  characterization of Staphylococcus aureus.
  Deplano A, Dodémont M, Denis O,et al. J Antimicrob Chemother 2018;73:2662-2666. doi: 10.1093/jac/dky260.

ESGITM

• National approaches to the vaccination of recently arrived migrants in Europe: A
  comparative policy analysis across 32 European countries.
  Ravensbergen SJ, Nellums LB, Hargreaves S, et al. Travel Med Infect Dis 2018. pii: S1477-8939(18)30366-1. doi: 10.1016/j.tmaid.2018.10.011.
• Two cases of imported hemorrhagic fever with renal syndrome and systematic
  review of literature.
  Puca E, Qato M, Pipero P, Akshija I, Kote M, Kraja D. Travel Med Infect Dis 2018. pii: S1477-8939(18)30240-0. doi: 10.1016/j.tmaid.2018.07.010.
• Refugees and family-reunified immigrants have a high incidence of HIV diagnosis
  and late presentation compared with Danish born: a nationwide register-based cohort study.
  Deen L, Cowan S, Wejse C, Petersen JH, Norredam M; ESCMID Study Group for Infections in Travellers and Migrants. Infection 2018;46:659-667. doi: 10.1007/s15010-018-1167-8.
• Who is responsible for the vaccination of migrants in Europe?
  Hargreaves S, Nellums LB, Ramsay M, et al. Lancet 2018;391:1752-1754. doi: 10.1016/S0140-6736(18)30846-8
• Screening for infectious diseases of asylum seekers upon arrival: the necessity
  of the moral principle of reciprocity.
  Beeres DT, Cornish D, Vonk M, et al. BMC Med Ethics 2018;19:16. doi: 10.1186/s12910-018-0256-7
• Interventions to improve vaccination uptake and cost effectiveness of vaccination
  strategies in newly arrived migrants in the EU/EEA: A systematic review.
  Hui C, Dunn J, Morton R, et al. Int J Environ Res Public Health 2018;15:2065. doi: 10.3390/ijerph15102065
• Health impacts of parental migration on left-behind children and adolescents:
  a systematic review and meta-analysis.
  Fellmeth G, Rose-Clarke K, Zhao C, et al. Lancet 2018;392:2567-2582. doi: 10.1016/S0140-6736(18)32558-3
• Vaccination status and needs of asylum-seeking children in Denmark:
  a retrospective data analysis.
  Nakken CS, Skovdal M, Nellums LB, Friedland JS, Hargreaves S, Norredam M. Public Health 2018;158:110-116. doi: 10.1016/j.puhe.2018.02.018
• Efficacy of ivermectin mass-drug administration to control scabies in asylum
  seekers in the Netherlands:A retrospective cohort study between January
  2014 – March 2016.
  Beeres DT, Ravensbergen SJ, Heidema A, et al. PLoS Negl Trop Dis 2018;12:e0006401. doi: 10.1371/journal.pntd.0006401
• How effective are approaches to migrant screening for infectious diseases in
  Europe? A systematic review.
  Seedat F, Hargreaves S, Nellums LB, Ouyang J, Brown M, Friedland JS. Lancet Infect Dis 2018;18:e259-e271. doi: 10.1016/S1473-3099(18)30117-8
• Divergent approaches in the vaccination of recently arrived migrants to Europe:
  a survey of national experts from 32 countries, 2017.
  Hargreaves S, Nellums LB, Ravensbergen SJ, Friedland JS, Stienstra Y, Euro Surveill 2018;23. doi: 10.2807/1560-7917.ES.2018.23.41.1700772.
• Multidrug-resistant tuberculosis treatment adherence in migrants: a systematic
  review and meta-analysis.
  Nellums LB, Rustage K, Hargreaves S, Friedland JS. BMC Med 2018;16:27. doi: 10.1186/s12916-017-1001-7.

ESGVH

• Hepatitis C: Is eradication possible?
  Lombardi A, Mondelli MU; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int 2018. doi: 10.1111/liv.14011.
• Model projections on the impact of HCV treatment in the prevention of HCV
  transmission among people who inject drugs in Europe.
  Fraser H, Martin NK, Brummer-Korvenkontio H, et al. J Hepatol 2018;68:402-411. doi: 10.1016/j.jhep.2017.10.010
• The success of HCV cure: every rose has thorns.
  Salmon-Ceron D, Mondelli MU, Matičič M, Arends JE. J Viral Hepat  2018;25:320-328. doi: 10.1111/jvh.12823.

EFISG

• Azole-resistance in Aspergillus terreus and related species: an emerging problem
  or a rare phenomenon?
  Zoran T, Sartori B, Sappl L et al. Front Microbiol 2018;9:516. doi: 10.3389/fmicb.2018.00516.

EVASG

• Influenza vaccination and prevention of antimicrobial resistance.
  Esposito S, Principi N; European Society of Clinical Microbiology Infectious Diseases (ESCMID) Vaccine Study Group (EVASG). Expert Rev Vaccines 2018;17:881-888. doi: 10.1080/14760584.2018.1525298.

• Influenza immunization policies: Which could be the main reasons for differences
  among countries?
  Principi N, Camilloni B, Esposito S; ESCMID Vaccine Study Group (EVASG). Hum Vaccin Immunother 2018;14:684-692. doi: 10.1080/21645515.2017.1405188.
• Vaccination of 50+ adults to promote healthy ageing in Europe: The way forward.
  Esposito S, Principi N, Rezza G, et al. Vaccine 2018;36:5819-5824. doi: 10.1016/j.vaccine.2018.08.041

ESGAP and ESGBIES

• Management of bloodstream infections by infection specialists: an international
  ESCMID cross-sectional survey.
  Diallo K, Thilly N, Luc A, et al. Int J Antimicrob Agents 2018. pii: S0924-8579(17)30444-2. doi: 10.1016/j.ijantimicag.2017.12.010.
• Management of bloodstream infections by infection specialists in France and
  Germany: a cross-sectional survey.
  Diallo K, Kern WV, de With K, Luc A, Thilly N, Pulcini C. Infection 2018;46:333-339. doi: 10.1007/s15010-018-1122-8

ESGAP and ESGMD

• Diagnostic stewardship: are we using the right term?
  Dyar OJ, Moran-Gilad J, Greub G, Pulcini C; ESGMD executive committee and the ESGAP executive committee. Clin Microbiol Infect 2018. pii: S1198-743X(18)30799-7. doi: 10.1016/j.cmi.2018.12.011.

ESGAP, ESGBIS and ESGIE

• Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative
  bacilli: an international ESCMID cross-sectional survey among infection diseases
  specialistspracticing in large hospitals.
  Papst L, Beović B, Pulcini C, et al. Clin Microbiol Infect 2018. pii: S1198-743X(18)30069-7. doi: 10.1016/j.cmi.2018.01.015.
• Towards precision medicine in sepsis: a position paper from the European Society
  of Clinical Microbiology and Infectious Diseases.
  Rello J, van Engelen TSR, Alp E, et al. Clin Microbiol Infect 2018;24:1264-1272. doi: 10.1016/j.cmi.2018.03.011.

To top